国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

美國(guó)Advanced Cell Technology, Inc.
美國(guó)先進(jìn)細(xì)胞技術(shù)公司，設(shè)在美國(guó)馬薩諸塞州伍斯特。 該公司首次利用克隆技術(shù)培育出人類早期胚胎。
是體細(xì)胞克隆、治療性克隆和胚胎干細(xì)胞、轉(zhuǎn)基因畜牧動(dòng)物生物反應(yīng)器等科技研發(fā)和產(chǎn)業(yè)化領(lǐng)域中的世界領(lǐng)導(dǎo)者。
ACT的體細(xì)胞克隆、胚胎干細(xì)胞和轉(zhuǎn)基因及基因工程這三大技術(shù)支柱，是農(nóng)業(yè)中畜牧業(yè)變革性發(fā)展的新動(dòng)力，是醫(yī)學(xué)領(lǐng)域內(nèi)實(shí)現(xiàn)再生治療性自體細(xì)胞、組織、器官和生物制藥等治療手段革命性創(chuàng)新的重要基礎(chǔ)，是再生醫(yī)學(xué)產(chǎn)業(yè)到來(lái)的驅(qū)動(dòng)器。

Advanced Cell Technology, Inc. (OTCBB:ACTC – News) is applying stem cell technology in the field of regenerative medicine to bring effective, patient-specific therapies to the bedside. The company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials shortly. The company is also rapidly moving towards human clinical trials for its embryonic stem cell therapies including its RPE and HG programs. ACT published positive data from animal studies for its RPE (retinal pigment epithelial) cell program for the treatment of retinal degenerative disorders completed in collaboration with the Casey Eye Institute at Oregon Health and Science University. The company also has GLP Safety Studies in process for its RPE Program. ACT published positive data in the journal NATURE Methods for its HG (hemangioblast) cell program for the treatment of blood and cardiovascular diseases. The company expects to file INDs for its RPE and HG programs in 2008. In August 2006, ACT announced a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occassions the creation of human embryonic stem cell lines without destroying the developmental potential of the embryos. ACT owns or licenses over 380 patents and patent applications.